Xbrane Biopharma (Q1 review): Funding outlook improved, FDA decision in November - Redeye

Xbrane delivered a quiet Q1, showing revenue of SEK17.3m reflecting product delivery to STADA. More consequential than the financials was the announcement that Intas will assume financing of Xdivane CMC costs from April (although at cost of optionality), materially reducing near-term dilution risk and allowing the program to proceed on plan toward a launch in conjunction with patent expiry.

Länk till analysen i sin helhet: https://www.redeye.se/research/1164187/xbrane-biopharma-q1-review-funding-overhang-alleviated-fda-decision-in-november?utm_source=finwire&utm_medium=RSS